Jamil M. Beg, MBA
Independent Board Observer

Jamil is a life science investor and company builder focused on advancing breakthrough science into transformational medicines for patients. Jamil joined SV Health Investors in January 2024 and is a Partner based in Boston. He works with founders, entrepreneurs, operators, and co-investors to establish and build new biotech startups, as well as fund and grow established private biotech companies across any stage of investment.

Prior to joining SV, Jamil founded and operated several biotech startups as well as invested across therapeutic areas, stages of technology platforms/assets, and modalities. Over his career, Jamil has been involved in over twenty private financings, seven public offerings, and three M&A transactions. He has operated in six venture-backed startups and contributed to the advancement of multiple FDA approved products. Select investments and operating roles include Akouos (NASDAQ: AKUS, acquired by Eli Lilly), Aprea (NASDAQ: APRE), Kinaset Therapeutics (founding investor), Nido Biosciences (founder), RallyBio (NASDAQ: RLYB), Sage Therapeutics (NASDAQ: SAGE), and Transave Inhalation Therapeutics (merged with Insmed). Jamil brings a wealth of entrepreneurial and operational expertise from his time building companies like Sage Therapeutics and Nido Biosciences and founding several stealth biotech startups.

Jamil earned his B.S.E. in Bioengineering and Master of Biotechnology degrees from the University of Pennsylvania. He earned his M.B.A. in Healthcare Management and Entrepreneurial Management from The Wharton School of the University of Pennsylvania where he was a recipient of the Henry J. Kaiser Family Foundation Merit Award.